NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
TRAVATAN (travoprost) by Alcon is acid, a prostaglandin analog is a selective fp prostanoid receptor agonist, which is believed to reduce iop by increasing uveoscleral outflow. First approved in 2001.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVATAN (travoprost) is a prostaglandin analog ophthalmic solution approved in 2001 for reducing intraocular pressure in glaucoma and ocular hypertension patients. It works as a selective FP prostanoid receptor agonist that increases uveoscleral outflow, though the exact mechanism remains incompletely understood. Administered as daily eye drops, it represents a foundational therapy in glaucoma management.
LOE Approaching
Product is in late-stage maturity with approaching loss of exclusivity, suggesting organizational focus on transition planning and managed decline strategies rather than growth initiatives.
Mechanism of Action
acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Started Feb 2026
510 enrolled
Glaucoma
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Started Dec 2025
30 enrolled
Open Angle Glaucoma (OAG)Ocular Hypertension (OH)
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Started Jun 2025
110 enrolled
Glaucoma
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Started Nov 2023
250 enrolled
Open Angle GlaucomaOcular Hypertension
Travoprost Intraocular Implant + iStent Infinite
Started Sep 2023
150 enrolled
Glaucoma, Open-Angle
Worked on TRAVATAN at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.